Yahoo Finance Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Arbutus Biopharma (NASDAQ:ABUS) First Quarter 2024 Results
Key Financial Results
Revenue: US$1.53m (down 77% from 1Q 2023).
Net loss: US$17.9m (loss widened by 9.4% from 1Q 2023).
US$0.10 loss per share (further deteriorated from US$0.10 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Arbutus Biopharma EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 43%. Earnings per share (EPS) exceeded analyst estimates by 7.8%.
Looking ahead, revenue is expected to decline by 1.0% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 18%.
Performance of the American Biotechs industry.
The company's shares are down 1.5% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Arbutus Biopharma (1 is a bit concerning) you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
